Altretamine / Hexalen: Overview

Modified on 2009/10/14 21:47 by admin
Altretamine, also known as Hexalen, is indicated for the treatment of patients with recurrent ovarian cancer following therapy with a cisplatin and/or alkylating agent-based combination. Hexalen interferes with the growth and spread of cancer cells, which eventually results in their destruction. The medication belongs to a group of drugs known as antineoplastics. Approved by the U.S. Food and Drug Administration in 1990 and made by MGI Pharma and U.S. Bioscience, Hexalen is available in capsule form.

Side effects include, but may not be limited to, seizures, dizziness, depression, weakness, fatigue, unusual bleeding, fever, numbness of the arms and legs, nausea, stomach cramps and appetite loss.

A black box warning on the labeling information for Hexalen indicates that only a physician experienced with the use of antineoplastics should administer the drug and that peripheral blood counts should be monitored monthly. Because of the possibility of neurotoxicity, a neurological examination should be conducted regularly.

See your doctor if you have experienced an adverse reaction after being administered Hexalen. In addition, it may be important to contact an attorney who can help you protect your legal rights. Please keep in mind that there may be time limits within which you must commence suit.

See Also

  1. Cancer Drugs: Overview
  2. Balance Problems: Overview
  3. Depression: Overview
  4. Excessive Bleeding: Overview
  5. Fatigue: Overview
  6. Nausea: Overview
  7. Seizures: Overview
  Name Size